For veterinary teams
Clinical Obesity
A disease-stage diagnosis, not a body condition score. Clinical obesity is excess adiposity that is causing, worsening, or sustaining objective harm in an individual dog or cat.
This page outlines how clinical obesity is defined, how it differs from excess adiposity as a finding, and a reproducible way to screen for it at every visit, grounded in the four-tier framework and the Three A’s.
The core distinction
Excess adiposity is a finding. Clinical obesity is a diagnosis.
Body condition score identifies adiposity; it does not, on its own, diagnose adiposity-related illness. A high BCS confirms excess fat. Whether that excess has become a disease in this patient is a separate clinical question, one answered by documented abnormality and plausible attribution, not by the chart alone.
Body-composition finding
Excess adiposity
Confirmed excess fat, usually BCS 8–9/9. A clinically important finding and potential disease process, but not, by itself, a disease-stage diagnosis.
Disease-stage diagnosis
Clinical obesity
Excess adiposity that is plausibly causing, worsening, or sustaining objective clinical signs, laboratory abnormalities, functional limitation, or quality-of-life impairment. A compromised patient who needs intervention.
Four-tier framework
One label cannot carry the clinical meaning
Adapting the logic of the 2025 Lancet Diabetes & Endocrinology Commission on Clinical Obesity to companion animals, the framework separates four states. They are not interchangeable: each carries different implications for documentation, communication, treatment intensity, and follow-up.
Scroll horizontally to see all columns →
| Classification | Typical BCS | Defining feature | Action |
|---|---|---|---|
| Overweight | 6–7/9 | Excess adiposity present; obesity-related dysfunction not established by BCS alone. | Counsel and monitor. At BCS 7/9, rapid gain, or clinical concern, trigger obesity-focused assessment. |
| Descriptive obesity | 8–9/9 | Excess adiposity confirmed; clinical classification not yet completed. | Perform appropriate assessment and apply the Three A’s. |
| Pre-clinical obesity | 8–9/9 | No adiposity-related dysfunction documented after appropriate assessment. | Begin structured intervention and scheduled reassessment, not benign, not watchful waiting. |
| Clinical obesity | Usually 8–9/9 | The Three A’s are documented: adiposity, objective abnormality, and plausible attribution. | Obesity-first, not obesity-only care: treat adiposity and concurrent disease; reassess over time. |
The Three A’s
What separates clinical obesity from a high score?
Clinical obesity is not diagnosed from body condition alone, nor from a coexisting disease alone. The diagnosis requires all three, documented in the individual patient.
A
Adiposity
Excess adiposity is confirmed. In most dogs and cats this is BCS 8–9/9; selected lower-threshold patients may qualify when morphometrics, weight trajectory, or body-composition findings support clinically meaningful excess.
A
Abnormality
An objective abnormality is present: clinical signs, laboratory or diagnostic-test findings, functional limitation, or clinically meaningful quality-of-life impairment.
A
Attribution
The abnormality is plausibly caused, worsened, or sustained by excess adiposity after weighing stronger alternative explanations. Where the link is plausible but unconfirmed, document suspected adiposity-related dysfunction and a reassessment plan.
All three are required. Adiposity plus abnormality without plausible attribution, or attribution without confirmed adiposity, does not establish clinical obesity.
How to screen
Screening begins with routine assessment, not a diagnosis
The pathway from excess adiposity to clinical obesity is reproducible and uses tools already in the room. It starts at every visit and escalates only when adiposity crosses a threshold or dysfunction is suspected.
Record four measures at every visit
Body-weight trend, BCS, MCS, and a concise nutritional history. Together these describe adiposity pattern, lean-mass status, and management context more reliably than body weight alone.
Score BCS on the 9-point scale using whole integers only. Record MCS separately using the descriptive WSAVA categories: normal, mild, moderate, or severe loss, graded at the worst-affected of five palpation sites. In patients with obesity, palpate firmly: subcutaneous fat can mask sarcopenic obesity.
Classify by body condition
BCS 6–7/9 is overweight; BCS 8–9/9 is the usual descriptive-obesity threshold. Treat the 9-point ceiling as a floor, not a cap. A 9/9 patient has at least about 40% body fat, and true adiposity may be higher.
At BCS 7/9 or higher, open the Minimum Obesity Database
A BCS of 7/9 or higher, or suspected adiposity-related dysfunction, triggers obesity-focused assessment. Establish or update the MOD as the structured baseline for staging and monitoring.
Apply the Three A’s to stage the patient
Adiposity + objective abnormality + plausible attribution → clinical obesity. Confirmed adiposity without documented dysfunction after appropriate assessment → pre-clinical obesity, which still warrants structured intervention and scheduled reassessment.
When attribution is uncertain or unsupported, document suspected adiposity-related dysfunction, concurrent condition, or comorbidity as appropriate; treat as indicated; manage excess adiposity when appropriate; and reassess over time.
The baseline workup
Minimum Obesity Database (MOD) and the Obesity Pentad
The MOD is this framework’s general-practice screening and monitoring set. It helps identify abnormalities that may support a clinical obesity diagnosis, but it is not, by itself, a diagnostic criterion.
Minimum Obesity Database (MOD)
- Body-weight trend, BCS, and MCS
- Structured nutritional history
- Physical examination
- Complete blood count
- Serum chemistry profile
- Urinalysis
Obesity Pentad
The Obesity Pentad is a focused review of five routinely available chemistry analytes:
- Fasting triglycerides
- Total cholesterol
- Glucose
- Alanine aminotransferase, ALT
- Alkaline phosphatase, ALP
These analytes help clinicians recognize lipid, glycemic, and hepatic-enzyme patterns that may warrant confirmation, monitoring, or targeted testing. A single abnormal value does not, by itself, diagnose clinical obesity.
Abnormal results require confirmation and attribution through the Three A’s. The MOD and Pentad identify abnormalities; they do not establish causation, staging, or clinical obesity on their own.
A note on precision
What clinical obesity is not
- Not a high BCS alone. A BCS of 8 or 9 identifies the usual obesity phenotype; it does not establish clinical obesity.
- Not a coexisting disease alone. An unrelated comorbidity in a patient with obesity is not, on its own, clinical obesity.
- Not an assumption. The diagnosis requires patient-specific evidence connecting excess adiposity to documented harm.
Framework adapted from the 2025 Lancet Diabetes & Endocrinology Commission on Clinical Obesity and its companion-animal application by German, Ward, Woods-Lee, and Churchill. BCS thresholds are operational clinical thresholds, not externally validated disease-stage cutoffs.
This page is intended for veterinary professionals and supports, but does not replace, individual clinical judgment. Classification and treatment decisions should be individualized to the patient.